top of page
Recent Posts

Dabrafenib + Trametinib Improve Overall Response Rates in Pediatric Patients with Low-Grade Gliomas

  • OPACC
  • Jun 9, 2022
  • 1 min read

The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas.


Comentarios


Archive
Search By Tags
Rama logo.png
cgcg logo.jpg

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

info@opacc.org

705-828-7965

  • Wix Facebook page
  • Wix Twitter page
  • Instagram Social Icon
  • YouTube Social  Icon
bottom of page